The Lundbeck Foundation increases its commitment to IO Biotech

12. January – (Image: IO Biotech)

The Lundbeck Foundation increases its commitment to IO Biotech as part of our 2030 strategy

The Lundbeck Foundation is joining forces with IO Biotech’s other current owners, Novo Holdings and Sunstone, to invest in a major new Series B financing round in this immune-oncology specialist that is attracting significant new international investors to Danish biotech.

With this step, the Lundbeck Foundation is embarking on the part of its 2030 strategy aimed at developing the Foundation’s portfolio of healthcare enterprises and stimulating collaboration between research and the business sector. The strategy broadens the investment framework for Lundbeckfonden Emerge by up to DKK 1 billion.

‘Our specific objective is to pave the way for new and better treatments for the many patients with disorders that can’t adequately be treated or cured today. And IO Biotech is a good example of this because the US Food and Drug Administration (FDA) recently granted a so-called Breakthrough Therapy designation for their product candidates for skin cancer,’ says Christian Elling, Managing Partner at Lundbeckfonden Emerge and member of IO Biotech’s board of directors.

The Lundbeck Foundation’s Danish biotech investments are grouped under Lundbeckfonden Emerge, which today has a portfolio of seven biotech companies, primarily based on Danish research. By facilitating the birth of brand-new Danish companies, the Lundbeck Foundation helps future-proof Denmark’s position as a leading life science nation.

‘If the ground-breaking research taking place in Denmark is to benefit patients, it must move out of the lab into the commercial world. We help with this by providing both funding and advice – giving these companies the robust support they need to develop,’ Elling says.

The Lundbeck Foundation has been involved in IO Biotech since 2015, and after this financing round – one of the largest Series B rounds in Europe in ten years – the Foundation will be the company’s largest shareholder.


For additional information

Christian Elling, Managing Partner, Lundbeckfonden Emerge, tel. +45 2062 1276

Jesper Sloth Møller, Media Relations Manager, the Lundbeck Foundation, tel. +45 2233 8601


Read more

About  The Lundbeck Foundation

About The Lundbeck Foundation Emerge

About IO Biotech 



The Lundbeck Foundation launches 2030 strategy with ambitious goals for grant and commercial activities
22. December 2020
Lundbeck foundation awards grants worth dkk 57 million to bold projects
15. December 2020
Cognitive training helped patients with bipolar disorder
9. December 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge